Key result
Fibrinolytic therapy significantly reduced mortality in animal models of acute lung injury compared to controls (RR 0.21).
Why the study?
Does fibrinolytic therapy improve physiological parameters and reduce mortality in animal models of acute lung injury?
Population
Animal models of acute lung injury from 22 preclinical studies, including both large animals and small…
Comparison
Fibrinolytic therapy including tissue-type… vs Control (vehicle, saline, or no treatment).
Design
Meta-analysis
Follow-up
6 hours to 30 days
Authors
Loading...
Does not support clinical use in acute lung injury; extends animal mortality data but leaves human efficacy open.
Meta-Analysis (n=200)
Does fibrinolytic therapy improve physiological parameters and reduce mortality in animal models of acute lung injury?
Relative Risk: 0.21 (95% CI 0.08–0.52)
Absolute Event Rate: 17% vs 87%
p-value: p=0.0008
In preclinical animal models of acute lung injury, fibrinolytic therapy significantly improves gas exchange, reduces lung inflammation, and decreases mortality.
Liu et al. (2018) conducted a meta-analysis in Acute lung injury (n=200). Fibrinolytic therapy (tPA, uPA, plasmin) vs. Control was evaluated on Mortality (RR 0.21, 95% CI 0.08-0.52, p=0.0008). Fibrinolytic therapy significantly reduced mortality in animal models of acute lung injury compared to controls (RR 0.21).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: